NEVVI Medicare utilization intelligence
or

← back

Provider profile

NATTAM, SREENIVASA MD

Hematology-Oncology · NPI 1982606893 · FORT WAYNE, IN

1
Groups
29
Codes · 2024
39,435
Disclosed services

NATTAM, SREENIVASA is a Hematology-Oncology in FORT WAYNE, IN, a member of 1 medical group, who billed 29 distinct codes to Medicare Part B in 2024.

Groups: AMERICAN ONCOLOGY PARTNERS PA (FORT WAYNE, IN)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

39,435
disclosed services
29
codes billed to Medicare Part B
Prior year · CY2023 48,988 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J2405 Injection, ondansetron hydrochloride, per 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
96372 Injection of drug or substance under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96361 Infusion into a vein for hydration, each additional hour
96417 Administration of additional new drug or substance into vein, 1 hour or less
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J7030 Infusion, normal saline solution , 1000 cc
96415 Administration of chemotherapy into vein, each additional hour
J1200 Injection, diphenhydramine hcl, up to 50 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
96360 Infusion into a vein for hydration, 31-60 minutes
J3490 Unclassified drugs
38222 Biopsy and aspiration of bone marrow sample for diagnosis
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.